DPP4 and stomach disorder: However, the current literature surrounding novel anti-diabetic agents such as sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase 4 inhibitors (DPP4I) on various gastric diseases remain controversial.